Previous 10 | Next 10 |
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million an...
Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39 th Annual J.P. Morgan Healthcare Conference at ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Neurocrine Biosciences (NBIX) and collaboration partner Voyager Therapeutics (VYGR) have announced that the FDA has put a clinical hold on RESTORE-1 trial evaluating NBIb-1817 (VY-AADC) in Parkinson's disease.The independent Data Safety Monitoring Board has requested additional patient level ...
CAMBRIDGE, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences (Nasdaq: NBIX) that it has placed a clinical hold on the RESTORE-1 clinical trial of NBIb-1817 (...
Neurocrine Biosciences Announces Repurchase of Convertible Notes PR Newswire SAN DIEGO, Nov. 19, 2020 SAN DIEGO , Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privat...
Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance. If COVID-19 is the true source of Ingrezza headwinds, quarterly sales growth could be under pressur...
Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q3 2020 Earnings Call Nov 9, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences Inc (NBIX) Q3 2020 Earnings Call Transcrip...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Neurocrine Biosciences, Inc. 2020 Q3 - Results - Earnings Call Presentation
Neurocrine Biosciences, Inc. (NBIX) Q3 2020 Earnings Conference Call November 9, 2020 16:30 ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...